



جمعية صيدلة المستشفيات
Society of Hospital Pharmacy



وزارة الصحة
Ministry of Health
المملكة العربية السعودية



BioLocal KSA Congress 2026

The Future Formulary:
Biosimilars, Localization, and Hospital System
Readiness



21-22 September
2026, Riyadh



Crowne Plaza Riyadh RDC
Riyadh, KSA



GOLD PARTNER



SILVER PARTNER



BRONZE PARTNERS



Strategic Partner

صندوق تنمية
الموارد البشرية
HUMAN RESOURCES
DEVELOPMENT FUND



THE POWER OF PRECISION¹

ONE GENE. ONE EDIT. ONE TIME.^{*1}

A precise, autologous, one-time, gene-editing therapy¹ that has the potential to provide a functional cure to eligible patients^{2,3}

CASGEVY is indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs).¹

CASGEVY is indicated for the treatment of transfusion-dependent β -thalassemia (TDT) in patients 12 years and older.¹

Visual for illustrative purposes only.

^{*1}The treatment process includes mobilization and apheresis, editing of the cells, myeloablative conditioning, CASGEVY[®] administration and long-term follow-up. This promotional material is intended for healthcare professionals only.

References: 1. CASGEVY[®] KSA Summary of Product Characteristics January 2026. 2. Eckrich MJ and Frangoul H. Semin Hematol. 2023;60(1):3-9. 3. EMA. Assessment report: CASGEVY. Available at: https://www.ema.europa.eu/en/documents/assessment-report/casgevy-epar-public-assessment-report_en.pdf. Accessed Oct 2025.

These preparations have several side effects. Please learn about them, consult your doctor or pharmacist, and read the medicine leaflet. If there are any side effects of the medications, please contact the Saudi Food and Drug Authority to report on the unified number, 19999.

Marketing Authorisation Holder: Vertex Pharmaceuticals (Europe) Limited 2 Kingdom Street, London, W2 6BD, United Kingdom.
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Cigalah Healthcare Company, Al Akariya Building Number 2 Olaya Street, Riyadh 11533, Kingdom of Saudi Arabia.

CASGEVY[®] is manufactured for Vertex Pharmaceuticals (Europe) Limited.
Vertex, the Vertex triangle logo, CASGEVY[®], and the CASGEVY[®] logo are registered trademarks of Vertex Pharmaceuticals Incorporated.
© 2025 Vertex Pharmaceuticals (Europe) Limited | SA-73-2600002 | 02/26

To report any side effect(s):
- The National Pharmacovigilance Centre (NPC):
- SFDA Call Center: 19999
- E-mail: npc.drug@sfd.gov.sa
- Website: <https://ade.sfda.gov.sa/>

Adverse Events Reporting: globalpatientsafety@vrtx.com
Patients' Complaints Reporting: VertexMedicalInfo@vrtx.com
Medical Information: 800-844-3907

For CASGEVY[®] KSA
Patient Information Leaflet,
please scan the QR Code



For CASGEVY[®] KSA
Summary of Product
Characteristics, please
scan the QR Code



**VERTEX**

DAY 1 | Monday, 21 September 2026

Policy, Regulation & System Readiness

Session 1

Chair & Moderator: **Dr. Mohammed Alshennawi**
General Administration of Pharmaceutical Care, MoH

09:00 – 09:30	Registration, welcome coffee & networking	
09:30 – 10:00	What a Biosimilar Really Is: The Molecular Science Behind Biologics Manufacturing	 Dr. Nadin Almosnid Director of Biotechnology Program King Saud bin Abdulaziz University for Health Sciences
10:00 – 10:30	Opening Ceremony Includes the Opening Keynote "Pharmaceutical Localization: Vision 2030 in Action"	
10:30 – 11:00	Made in Saudi: The Industrial Strategy for Pharmaceutical Manufacturing	 Dr. Mohamed Alfaleh Ministry of Industry & Mineral Resources
11:00 – 11:30	The Manufacturer's Perspective: Building Saudi Biologics Capacity the Hospital Formulary Can Rely On	 Dr. Yasser Alobaida Chief Executive Officer and Founder at Sudair Pharma
11:30 – 12:30	Panel Discussion From Formulary to Factory: The Vision for Saudi Localization 2030	 • Dr. Mohamed Alfaleh • Dr. Ashraf AlGrain • Dr. Nadin Almosnid • Dr. Yasser Alobaida • Dr. Sarah Aref
12:30 – 13:30	Prayer & Lunch	

DAY 1 | Monday, 21 September 2026

Policy, Regulation & System Readiness

Session 2

Chair & Moderator : **Dr. Abdulaziz Alhossan**

13:30 – 14:00	The SFDA Biosimilar Regulatory Pathway: Current State & Future Direction	 Dr. Ali Alsamil SFDA – Drug Sector
14:00 – 14:30	National Drug Policy for Biosimilars: From Listing Decision to Hospital Formulary	 Dr. Amirah Alnahdi Head of Drug Information Centers Drug policy and regulation General Administration of Pharmaceutical Care, MOH
	Keynote	
14:30 – 15:00	NUPCO's Experience with Biosimilars & Localized Portfolios	 Dr. Waleed bin Saleh Al-Mutaiwee NUPCO
15:00 – 15:30	The Economics of Switching: Budget Impact, Gainsharing and Where the Savings Go	 Dr. Fatima Alyami CNHI
15:30 – 16:00	Hospital System Readiness: The National Picture	 Dr. Mohammed Alshennawi General Administration of Pharmaceutical Care, MoH
16:00 – 16:30	Gene therapy: Recent Updates in Hemoglobinopathies <i>Symposium - Vertex</i>	 Dr. Ibrahim Meatebi Hematologist at King Fahad Medical City
16:30 – 17:00	Discussion	 Dr. Mohammed Alshennawi Dr. Tawfiq Alohal Dr. Ali Alsamil Dr. Amirah Alnahdi Dr. Fatima Alyami
17:00	Closing	

DAY 2 | Tuesday, 22 September 2026

Clinical Evidence & Hospital Practice

Session 3

Chair & Moderator : **Dr. Alaa Mutlaq**

08:00 – 09:00 **Registration & coffee**

09:00 – 09:30 **Funding the Unaffordable:
How Health Systems Pay for Cell & Gene Therapies**

 **Dr. Hana Alabdulkarim**
Corporate Director, Drug Policy and Economic Centre
Ministry of National Guards Health Affairs, Saudi Arabia

09:30 – 10:00 **From Protocol to Patient: Frontline Lessons
from an Outpatient Biosimilar Switch Program**

 **Dr. Hala Joharji**
Corporate Executive Director
of Pharmaceutical Care Services,
Dr. Sulaiman Alhabib Medical Group

10:00 – 10:30 **Switching Protocols:
From Reference Biologic to Biosimilar**

 **Dr. Wejdan Aburas**
Senior Clinical Benefit Assessment Specialist,
Center for National Health Insurance (CNHI)

10:30 – 11:00 **From bench to bed-side: Spimaco's
experience in localizing biologicals**

 **Prof. Ahmed Aljedai**

11:00 – 12:00 **Panel Discussion
Formulary Decisions in Practice**

 **. Dr. Hana Alabdulkarim**
. Dr. Hala Joharji
. Dr. Wejdan Aburas
. Dr. Mohammed Alshennawi

12:00 – 13:30 **Prayer & Lunch**

DAY 2 | Tuesday, 22 September 2026

Session 4

Chair & Moderator : **Dr. Nada Alagil**

13:30 – 14:00	The Prescriber's View: What Makes a Physician Hesitate to Switch and What Changes That	 Dr. Ibrahim Alhomood Consultant Rheumatologist & Internist King Fahad Medical City (KFMC), Riyadh
14:00 – 14:30	Biosimilars in Diabetes: Devices, Titration and the Conversion Playbook	 Dr. Saud Alsifri Consultant Endocrinologist & Diabetes Al Hada & Taif Armed Forces Hospitals, Taif
14:30 – 15:00	Biosimilars in IBD: Extrapolation, Therapeutic Drug Monitoring and Loss of Response	 Dr. Ebtissam AlMeghaiseeb Senior Consultant Gastroenterologist, Hepatologist & IBD Specialist Prince Sultan Military Medical City (PSMMC)
15:10 – 15:40	Panel Discussion Making the Switch Work in Practice	 Dr. Ibrahim Alhomoud Dr. Saud Alsifri Dr. Ebtissam AlMeghaiseeb
15:40 – 16:00	From Policy to Practice: Hands-On Implementation Begins	 Dr. Mohammed Alshennawi General Administration of Pharmaceutical Care, MoH